Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Monthly Archives: January 2013

Ledger Opinion: NJLSVA’s Don Sico: ‘New Jersey’s Economy Tied to Medical Innovation’

New Brunswick, NJ, January 15, 2013The Star-Ledger today published an opinion piece by Donald Sico, the executive director of the New Jersey Life Sciences Vendors Alliance (NJLSVA), entitled “New Jersey’s Economy Tied to Medical Innovation.”  Sico wrote, in part:

“Maintaining its leadership in medical innovation is an economic priority for New Jersey.  Medical innovation involves the success not just of big-time, research-based biopharmaceutical and medical technology companies, but also of the thousands of suppliers who provide critical goods and services on which they draw.

“These vendors conduct clinical trials, help companies maintain compliance with government regulations, make the specialized equipment needed for research and production, provide transportation, offer legal counsel on patents and other matters, and manufacture the final product.

“This comprehensive and specialized supply chain, which has steadily evolved and grown to meet the needs of the state’s life sciences industry over the past 126 years, is another key reason why New Jersey continues to be a global hub for biopharmaceutical and medical technology companies.

“Directly and through spin-off effects, the biopharmaceutical sector of New Jersey supports 425 of every 10,000 jobs in our state, according to a report by the consulting group Archstone.  That’s the highest percentage of any state.  The sector employs more than 52,000 people directly, supports more than 75,000 jobs elsewhere in the New Jersey economy, and contributes more than $58 billion to the state’s economic output.

“The breadth and depth of New Jersey’s life sciences supply chain is unmatched and its economic impact to the state is vast.  Major biopharmaceutical companies report that they have nearly 16,000 relationships with New Jersey-based vendors and purchase more than $8 billion worth of goods and services from them annually.

“The New Jersey Life Science Vendor Alliance, with more than 700 members, shares a common interest in advancing and protecting this critical segment of our state’s economy.”

To read Sico’s complete opinion piece, click here.